Intratumoral therapy of glioblastoma multiforme using genetically engineered transferrin for drug delivery

Cancer Research

Volumn 70, Issue 11, 2010, Pages 4520-4527

  Yoon, Dennis J ^a   Kwan, Byron H ^a   Chao, Felix C ^a   Nicolaides, Theodore P ^b   Phillips, Joanna J ^c   Lam, Gretchen Y ^a   Mason, Anne B ^d   Weiss, William A ^b   Kamei, Daniel T ^a  

^a University of California   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IRON; TRANSFERRIN DIPHTHERIA TOXIN CONJUGATE; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG PURIFICATION; DRUG SYNTHESIS; FEMALE; GENE DELIVERY SYSTEM; GENETIC ENGINEERING; GLIOBLASTOMA; GLIOMA; GLIOMA CELL; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CRICETINAE; DIPHTHERIA TOXIN; DRUG DELIVERY SYSTEMS; FEMALE; GENETIC ENGINEERING; GLIOBLASTOMA; HUMANS; IMMUNOTOXINS; MICE; MICE, NUDE; MUTAGENESIS, SITE-DIRECTED; RECOMBINANT PROTEINS; TRANSFERRIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77953155086     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-4311     Document Type: Article

References (36)

1. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008;359:492-507.
2. Welch M, Lai R. Glioblastoma multiforme. Curr Treat Options Neurol 2009;11:297-305.
3. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
4. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
5. Weaver M, Laske DW. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol 2003;65:3-13.
6. Laske DW, Youle RJ, Oldfield EH. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 1997;3:1362-8.
7. Hou LC, Veeravagu A, Hsu AR, Tse VC. Recurrent glioblastoma multiforme: a review of natural history and management options. Neurosurg Focus 2006;20:E5.
8. Morokoff AP, Novak U. Targeted therapy for malignant gliomas. J Clin Neurosci 2004;11:807-18.
9. Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Bigner DD. Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin Immunol 2008;20:267-75.
10. Reardon DA, Akabani G, Coleman RE, et al. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 2002;20:1389-97.
11. Gatter KC, Brown G, Trowbridge IS, Woolston RE, Mason DY. Transferrin receptors in human tissues: their distribution and possible clinical relevance. J Clin Pathol 1983;36:539-45.
12. Niitsu Y, Kohgo Y, Nishisato T, et al. Transferrin receptors in human cancerous tissues. Tohoku J Exp Med 1987;153:239-43.
13. Qian ZM, Li H, Sun H, Ho K. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol Rev 2002;54:561-87.
14. Debinski W. Molecular targeting with recombinant cytotoxins for the treatment of brain tumors. Drug Dev Res 2008;69:407-14.
15. Lao BJ, Tsai WL, Mashayekhi F, Pham EA, Mason AB, Kamei DT. Inhibition of transferrin iron release increases in vitro drug carrier efficacy. J Control Release 2007;117:403-12.
16. Lin LN, Mason AB, Woodworth RC, Brandts JF. Calorimetric studies of the binding of ferric ions to human serum transferrin. Biochemistry 1993;32:9398-406.
17. Ponka P, Lok CN. The transferrin receptor: role in health and disease. Int J Biochem Cell Biol 1999;31:1111-37.
18. Cazzola M, Bergamaschi G, Dezza L, Arosio P. Manipulations of cellular iron metabolism for modulating normal and malignant cell proliferation: achievements and prospects. Blood 1990;75:1903-19.
19. Klausner RD, Van Renswoude J, Ashwell G, et al. Receptor-mediated endocytosis of transferrin in K562 cells. J BiolChem1983;258:4715-24.
20. Johnson VG, Wilson D, Greenfield L, Youle RJ. The role of the diphtheria toxin receptor in cytosol translocation. J Biol Chem 1988;263:1295-300.
21. Halbrooks PJ, He QY, Briggs SK, et al. Investigation of the mechanism of iron release from the C-lobe of human serum transferrin: mutational analysis of the role of a pH sensitive triad. Biochemistry 2003;42:3701-7.
22. He QY,Mason AB,TamBM,MacGillivray RT, Woodworth RC. Dual role of Lys206-296 interaction in human transferrin N-lobe: iron-release trigger and anion-binding site. Biochemistry 1999;38:9704-11.
23. Yoon DJ, Chu DS, Ng CW, et al. Genetically engineering transferrin to improve its in vitro ability to deliver cytotoxins. J Control Release 2009;133:178-84.
24. Fan QW, Weiss WA. RNA interference against a glioma-derived allele of EGFR induces blockade at G2M. Oncogene 2005;24:829-37.
25. Mason AB, He QY, Halbrooks PJ, et al. Differential effect of a his tag at the N- and C-termini: functional studies with recombinant human serum transferrin. Biochemistry 2002;41:9448-54.
26. Mason AB, He QY, Adams TE, et al. Expression, purification, and characterization of recombinant nonglycosylated human serum transferrin containing a C-terminal hexahistidine tag. Protein Expr Purif 2001;23:142-50.
27. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107-12.
28. Laske DW, Ilercil O, Akbasak A, Youle RJ, Oldfield EH. Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice. J Neurosurg 1994;80:520-6.
29. Yazdi PT, Murphy RM. Quantitative analysis of protein synthesis inhibition by transferrin-toxin conjugates. Cancer Res 1994;54:6387-94.
30. Gosselaar PH, van-Dijk AJG, de-Gast GC, et al. Transferrin toxin but not transferrin receptor immunotoxin is influenced by free transferrin and iron saturation. Eur J Clin Invest 2002;32:61-9.
31. Byrne SL, Mason AB. Human serum transferrin: a tale of two lobes. Urea gel and steady state fluorescence analysis of recombinant transferrins as a function of pH, time, and the soluble portion of the transferrin receptor. J Biol Inorg Chem 2009;14:771-81.
32. MacGillivray RT, Moore SA, Chen J, et al. Two high-resolution crystal structures of the recombinant N-lobe of human transferrin reveal a structural change implicated in iron release. Biochemistry 1998;37:7919-28.
33. Angelova-Gateva P. Iron transferrin receptors in rat and human cerebrum. Agressologie 1980;21:27-30.
34. Jefferies WA, Brandon MR, Hunt SV, Williams AF, Gatter KC, Mason DY. Transferrin receptor on endothelium of brain capillaries. Nature 1984;312:162-3.
35. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A 1994;91:2076-80.
36. Bidros DS, Vogelbaum MA. Novel drug delivery strategies in neurooncology. Neurotherapeutics 2009;6:539-46.